Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board (DSMB) has completed an interim analysis of a phase II trial (the LIPLONG study) of the company's long-acting recombinant factor VIII, BAY79-4980. The DSMB concluded that the study will not be able to achieve the predetermined efficacy endpoint (non-inferiority). No safety concerns were raised.
Bayer to discontinue the LIPLONG study
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany has announced that an independent Data Safety and Monitoring Board (DSMB) has completed an interim analysis of a phase II trial (the LIPLONG study) of the company's long-acting recombinant factor VIII, BAY79-4980. The DSMB concluded that the study will not be able to achieve the predetermined efficacy endpoint (non-inferiority). No safety concerns were raised.
Novo Nordisk receives approval for Victoza® in Japan
- Details
- Category: Novo Nordisk
Novo Nordisk announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes.
Sanofi-aventis and employees unite for the victims of Haiti
- Details
- Category: Sanofi
In the face of the unprecedented earthquake that hit the island of Haiti, sanofi-aventis has committed 1 million Euros in financial aid to long-term reconstruction initiatives and the rehabilitation of the population of Haiti.
Three new Novartis medicines approved in Japan
- Details
- Category: Novartis
Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union, for the treatment of type 2 diabetes, Exforge® (valsartan/amlodipine) for high blood pressure, and Afinitor® (everolimus) for advanced kidney cancer. These approvals reinforce the strong commitment of Novartis to helping patients in Japan, the company's second-largest pharmaceutical market.
Bristol-Myers Squibb supporting efforts to help survivors
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb is joining the world community in providing immediate help for survivors of the massive earthquake that struck Haiti on January 12. The company has already shipped a large donation of antibiotics through Project Hope, an organization providing direct relief to disaster victims.
Lilly Sends Relief to Haiti Earthquake Victims
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) will provide donations of medicines and money for victims of the catastrophic earthquake in Haiti on January 12. Lilly has initially pledged $250,000 in direct cash contributions.
More Pharma News ...
- Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
- Novartis providing equivalent of over USD 2.5 million for victims of Haiti earthquake
- Amgen Donates $2 Million, Establishes Earthquake Relief Program
- Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti
- Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
- FDA approves ACTEMRA for the treatment of moderately to severely active rheumatoid arthritis
- Genzyme Reports Fourth-Quarter Revenue